Compugen Ltd. (NASDAQ:CGEN)‘s stock had its “buy” rating reissued by research analysts at FBR & Co in a research report issued on Tuesday.

Separately, Zacks Investment Research upgraded shares of Compugen from a “sell” rating to a “hold” rating in a research report on Tuesday, August 2nd. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $10.40.

Analyst Recommendations for Compugen (NASDAQ:CGEN)

Shares of Compugen (NASDAQ:CGEN) traded up 3.686% during mid-day trading on Tuesday, hitting $6.273. The company’s stock had a trading volume of 51,206 shares. The company has a 50-day moving average price of $6.13 and a 200-day moving average price of $6.58. The stock’s market cap is $319.47 million. Compugen has a 1-year low of $4.32 and a 1-year high of $7.79.

Compugen (NASDAQ:CGEN) last released its quarterly earnings data on Monday, November 7th. The company reported ($0.15) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.14) by $0.01. Compugen had a negative net margin of 261.77% and a negative return on equity of 29.33%. Analysts predict that Compugen will post ($0.61) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Compugen’s (CGEN) “Buy” Rating Reiterated at FBR & Co” was originally reported by Daily Political and is the propert of of Daily Political. If you are viewing this news story on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The correct version of this news story can be read at http://www.dailypolitical.com/2016/11/29/compugens-cgen-buy-rating-reiterated-at-fbr-co.html.

Institutional investors have recently added to or reduced their stakes in the company. Rock Springs Capital Management LP boosted its position in Compugen by 0.6% in the third quarter. Rock Springs Capital Management LP now owns 825,000 shares of the company’s stock worth $5,198,000 after buying an additional 5,000 shares during the period. Vanguard Group Inc. boosted its position in Compugen by 12.4% in the second quarter. Vanguard Group Inc. now owns 740,047 shares of the company’s stock worth $4,796,000 after buying an additional 81,729 shares during the period. Morgan Stanley boosted its position in Compugen by 1.9% in the third quarter. Morgan Stanley now owns 713,710 shares of the company’s stock worth $4,496,000 after buying an additional 13,630 shares during the period. BlackRock Fund Advisors boosted its position in Compugen by 4.6% in the third quarter. BlackRock Fund Advisors now owns 671,557 shares of the company’s stock worth $4,231,000 after buying an additional 29,402 shares during the period. Finally, Rothschild Investment Corp IL boosted its position in Compugen by 2.2% in the second quarter. Rothschild Investment Corp IL now owns 458,510 shares of the company’s stock worth $2,971,000 after buying an additional 10,000 shares during the period. Hedge funds and other institutional investors own 17.25% of the company’s stock.

About Compugen

Compugen Ltd. (Compugen) is a therapeutic discovery company. The Company focuses on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins in the fields of oncology and immunology. Its pipeline program consists of drug targets and therapeutic product candidates at various stages ranging from target validation to pre-clinical studies in the fields of oncology and immunology, with a primary focus on immuno-oncology.

5 Day Chart for NASDAQ:CGEN

Receive News & Ratings for Compugen Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.